EPCAM and pancreatic neoplasm: However, recent development of a cancer immunotherapy using an anti-EPCAM monoclonal antibody conjugated with α-AMA demonstrated clear growth suppression effects in a human pancreatic cancer mouse skin xenograft model without systemic side effects even at a dose of 0.1 mg/kg40.